November 30, 2018
Eureka Therapeutics Announces Data Presentations Validating its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting
November 21, 2018
Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome (CRS) and Neurotoxicity
September 5, 2018
Eureka Therapeutics Achieves Regression of Metastatic Liver Cancer using ET140202 T-cell Therapy
August 30, 2018
Eureka Therapeutics to Present Proof-of-Concept Preliminary Data from Ongoing China Clinical Study of ET140202 at CAR-TCR 2018 Summit
August 16, 2018
Eureka Therapeutics Announces Publication of Armored T-Cell Proof-of-Concept Study in Nature Biotechnology
July 17, 2018
Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodies
July 16, 2018
Eureka Expands Scientific Advisory Board Members with Addition of Cytokine Release Syndrome (CRS) Experts Stephan A. Grupp, M.D., Ph.D. and Cameron J. Turtle, MBBS, Ph.D., FRACP, FRCPA
June 4, 2018
Eureka Therapeutics Announces Positive Preliminary Results Of ET190L1 ARTEMIS™ T-Cell China Proof-Of-Concept Human Clinical Study In Relapsed And Refractory B-Cell Lymphoma At ASCO Annual Meeting
January 22, 2018
Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies
